News and Press Releases

Prosarix contributes to Prolysis' discovery of novel antibacterials, now published in Science

Cambridge, UK, September 24th 2008 — Prolysis Ltd, an antibacterial drug discovery company based in Oxford, UK, has published the discovery of a new class of antibacterials in the the prestigious international journal, Science. As a partner to Prolysis, Prosarix carried out the computational chemistry component of this work, which utilised elements of its ProtoDiscovery™ platform.

The paper describes the discovery of a new and efficacious bactericidal class of antibacterials that kill staphylococci by inhibiting their cell division process. The success of these inhibitors against a novel target site and their potential to treat drug-resistant infections is a significant event in this therapeutic area.